Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Cancer Chemother Pharmacol. 2017 Jun 2;80(1):165–175. doi: 10.1007/s00280-017-3346-1

Fig. 3.

Fig. 3

Model diagnostics. There was no trend in the CWRES vs PRED (a), confirming adequacy of structural model; nor any trend in DV vs IPRED (b), suggesting the residual or unexplained variability (RUV) model was adequate. Random effects calculated were normally distributed (c, d)